| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The complement system plays a critical role in both innate and adaptive immune responses. We found locally produced complement component 3 (C3) from renal allografts and downregulation of complement regulatory factor(CRF) activated the complement system during acute cellular rejection in animal models. When anti-CRF antibody was injected, acute cellular rejection was promoted. Moreover, We demonstrated that CD46 expression in human renal tubular cells during acute cellular rejection may influence the outcome of treatment and graft survival. Grafts from older donors may be a risk factor for decreased expression of CD46 in renal tubular cells. The clinical application of complement regulatory protein including CD46 and complement regulatory drugs is considered to have some potential for suppressing acute cellular rejection after transplantation and to improve graft outcome.
|
